These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 28989016

  • 1. Solubilization of a Poorly Soluble B-Raf (Rapidly Accelerated Fibrosarcoma) Inhibitor: From Theory to Application.
    Bao L, An L, Ran Y.
    J Pharm Sci; 2018 Jan; 107(1):327-333. PubMed ID: 28989016
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An Investigation of Oral Exposure Variability and Formulation Strategy: A Case Study of PI3Kδ Inhibitor and Physiologically Based Pharmacokinetic Modeling in Beagle Dogs.
    Chiang PC, Pang J, Liu J, Salphati L.
    J Pharm Sci; 2018 Jan; 107(1):466-475. PubMed ID: 28652157
    [Abstract] [Full Text] [Related]

  • 4. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
    Li S, Pollock-Dove C, Dong LC, Chen J, Creasey AA, Dai WG.
    Mol Pharm; 2012 May 07; 9(5):1100-8. PubMed ID: 22376012
    [Abstract] [Full Text] [Related]

  • 5. Solubilization and preformulation studies on PG-300995 (an anti-HIV drug).
    Ran Y, Jain A, Yalkowsky SH.
    J Pharm Sci; 2005 Feb 07; 94(2):297-303. PubMed ID: 15570598
    [Abstract] [Full Text] [Related]

  • 6. Solubilization of two structurally related anticancer drugs: XK-469 and PPA.
    He Y, Tabibi SE, Yalkowsky SH.
    J Pharm Sci; 2006 Jan 07; 95(1):97-107. PubMed ID: 16315229
    [Abstract] [Full Text] [Related]

  • 7. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM, Beig A, Carr RA, Spence JK, Dahan A.
    Mol Pharm; 2012 Jul 02; 9(7):2009-16. PubMed ID: 22632106
    [Abstract] [Full Text] [Related]

  • 8. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
    Miller JM, Beig A, Carr RA, Webster GK, Dahan A.
    Mol Pharm; 2012 Mar 05; 9(3):581-90. PubMed ID: 22280478
    [Abstract] [Full Text] [Related]

  • 9. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material.
    Dai WG, Dong LC, Li S, Pollock-Dove C, Chen J, Mansky P, Eichenbaum G.
    Int J Pharm; 2007 May 04; 336(1):1-11. PubMed ID: 17178444
    [Abstract] [Full Text] [Related]

  • 10. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL.
    Eur J Pharm Sci; 2015 Aug 30; 76():203-12. PubMed ID: 25978875
    [Abstract] [Full Text] [Related]

  • 11. Co-solubilization of poorly soluble drugs by micellization and complexation.
    Rao VM, Nerurkar M, Pinnamaneni S, Rinaldi F, Raghavan K.
    Int J Pharm; 2006 Aug 17; 319(1-2):98-106. PubMed ID: 16765542
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents.
    Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y.
    Eur J Pharm Sci; 2006 May 17; 28(1-2):7-14. PubMed ID: 16406526
    [Abstract] [Full Text] [Related]

  • 14. Solubilization of monovalent weak electrolytes by micellization or complexation.
    He Y, Yalkowsky SH.
    Int J Pharm; 2006 May 11; 314(1):15-20. PubMed ID: 16580158
    [Abstract] [Full Text] [Related]

  • 15. Solubilization of cyclosporin A.
    Ran Y, Zhao L, Xu Q, Yalkowsky SH.
    AAPS PharmSciTech; 2001 Jan 18; 2(1):E2. PubMed ID: 14727890
    [Abstract] [Full Text] [Related]

  • 16. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL, Trevaskis NL, Feeney OM, Edwards GA, Perlman ME, Ambler CM, Porter CJH.
    Mol Pharm; 2017 Dec 04; 14(12):4525-4538. PubMed ID: 29076741
    [Abstract] [Full Text] [Related]

  • 17. Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes.
    Buchanan CM, Buchanan NL, Edgar KJ, Lambert JL, Posey-Dowty JD, Ramsey MG, Wempe MF.
    J Pharm Sci; 2006 Oct 04; 95(10):2246-55. PubMed ID: 16886192
    [Abstract] [Full Text] [Related]

  • 18. Drug solubilization by complexation.
    Loftsson T.
    Int J Pharm; 2017 Oct 05; 531(1):276-280. PubMed ID: 28842309
    [Abstract] [Full Text] [Related]

  • 19. Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin.
    Tommasini S, Calabrò ML, Raneri D, Ficarra P, Ficarra R.
    J Pharm Biomed Anal; 2004 Oct 29; 36(2):327-33. PubMed ID: 15496325
    [Abstract] [Full Text] [Related]

  • 20. Current perspectives of solubilization: potential for improved bioavailability.
    Mallick S, Pattnaik S, Swain K, De PK.
    Drug Dev Ind Pharm; 2007 Aug 29; 33(8):865-73. PubMed ID: 17729104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.